SCHEMBL8701366

SCHEMBL8701366

C[C@H]1N[C@H](C(=O)O)Cc2cc(O)ccc21

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
ESR1 P03372 5/20 0.38
OPRM1 P35372 2/20 0.38
BDKRB2 P30411 1/20 0.38
ADORA1 P30542 1/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
SHBG P04278 1/20 0.37
ESR2 Q92731 1/20 0.35
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KDM4E B2RXH2 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
UBA1 P22314 2/20 0.34
GPER1 Q99527 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5325492 1.00 CHRNB2 (0.39) CHRNB2CHRNA4ESR1OPRM1BDKRB2
SCHEMBL28197625 1.00 CHRNB2 (0.39) CHRNB2CHRNA4ESR1OPRM1BDKRB2
Hydrochloric Acid SCHEMBL22574492 0.87 OPRM1 (0.39) OPRM1GAAMAPTOPRD1OPRK1
SCHEMBL28813162 0.81 MAOA (0.46) GAAMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL5131200 0.81 MAOA (0.46) GAAMAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL8704991 0.81 SHBG (0.40) CHRNB2CHRNA4ESR1OPRM1BDKRB2
SCHEMBL8724857 0.81 ALDH1A1 (0.44) CHRNB2CHRNA4ESR1GAAALDH1A1
SCHEMBL8722537 0.80 MAPT (0.51) OPRM1GAAMAPTALDH1A1KDM4E
SCHEMBL28197623 0.80 MAPT (0.51) OPRM1GAAMAPTALDH1A1KDM4E
SCHEMBL31505403 0.79 CHRNB2 (0.44) CHRNB2CHRNA4ESR1OPRM1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1998056790-A1 DIHYDROIMIDAZO[1,5-B]ISOQUINOLINE-1,3-DIONES AS APOPROTEIN B-100 INHIBITORS GLAXO GROUP LIMITED (GB) 1998-12-17 WO disclosed